The device takes advantage of the fact that when one exhales, the soft palate closes off the airway access to the oral cavity, creating optimal dispersion of the medication, thus avoiding any lung deposition of the medication.
The TriVair™ patented device uses the body’s natural breath to propel powder medications high and deep into the nasal cavity. It reaches sites (olfactory nerve & SPG) not reached by standard nasal sprays, thus enabling a rapid onset of action, and the potential of bypassing the Blood Brain Barrier.
With the TriVair™ device and its patented plume geometry the medication is evenly distributed throughout the nasal mucosa.
TriVair™’s intranasal delivery avoids systemic delivery and potential GI side effects.
The TriVair™ delivery system would be excellent for any API targeting the CNS (Central Nervous System), with either new or existing drugs, including vaccines and medical cannabis.
TriVair™ has the potential to significantly improve the lives of patients, transform the nasal delivery arena and become the dominant nasal drug delivery platform of the future by making good medicines great!
